Ligons Frank M, Mello-Thoms Claudia, Handler Steven M, Romagnoli Katrina M, Hochheiser Harry
Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, United States; Geriatric Pharmaceutical Outcomes and Geroinformatics Research & Training Program, University of Pittsburgh, Pittsburgh, PA, United States.
Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, United States; Medical Radiation Sciences, The University of Sydney, Sydney, NSW, Australia.
Int J Med Inform. 2014 Nov;83(11):841-8. doi: 10.1016/j.ijmedinf.2014.07.004. Epub 2014 Jul 27.
To examine the relationship between cognitive status and the usability of an integrated medication delivery unit (MDU) in older adults who reside in an Assisted Living Facility (ALF).
Subjects were recruited from a single ALF in Pittsburgh, PA. Usability testing sessions required subjects to execute tasks essential to using EMMA(®) (Electronic Medication Management Assistant), a Class II Federal Drug Administration (FDA) approved integrated MDU. Video coding allowed for quantification of usability errors observed during the testing sessions. Each subject's cognitive status was assessed using the Mini Mental State Exam (MMSE(®)) with scores <24 indicating cognitive impairment. Functional status was assessed using the Lawton Instrumental Activities of Daily Living (IADL) questionnaire, and a global assessment of subjective usability was assessed by completing the System Usability Scale (SUS). Non-parametric statistics and correlation analysis were used to determine whether significant differences existed between cognitively impaired and non-impaired subjects.
Nineteen subjects were recruited and completed the protocol. The subject pool was primarily white, female, 80+ and in possession of above average education. There was a significant relationship between MMSE(®) scores and the percentage of task success (z=-2.03, p=0.04). Subjects with MMSE(®) scores of 24+ (no cognitive impairment) successfully completed an average of 69.0% of tasks vs. the 34.7% performance for those in the cognitively impaired group (<24). Six of the unimpaired group also succeeded at meeting the 85% (6 out of 7 correct) threshold. No subject with cognitive impairments (<24 MMSE(®)) completed more than 5/7 (71.4%) of their tasks. Two of the impaired subjects failed all of the tasks. Three of the MMSE(®)'s subsections (Date, Location and Spell 'world' backwards) were found to be significantly related (p<0.05) to the percentage of task success. Tasks success rates were related with IADL scores (z=-3.826, p<0.0001), and SUS scores (r=0.467, p=0.0429).
Medication delivery units like EMMA(®) have the potential to improve medication management by combining reminder systems with telemedical monitoring and control capabilities. However, subjects judged to be "cognitively impaired" (<24 MMSE(®)) scored a significantly smaller percentage of task success than the "unimpaired" (>=24), suggesting that cognitive screening of patients prior to the use of EMMA(®) may be advisable. Further studies are needed to test the use of EMMA(®) amongst ALF residents without cognitive impairment to see if this technology can improve medication adherence.
研究居住在辅助生活设施(ALF)中的老年人认知状态与集成给药装置(MDU)可用性之间的关系。
从宾夕法尼亚州匹兹堡的一个单一ALF招募受试者。可用性测试环节要求受试者执行使用EMMA(®)(电子药物管理助手,一种经美国食品药品监督管理局(FDA)批准的II类集成MDU)所需的基本任务。视频编码可对测试环节中观察到的可用性错误进行量化。使用简易精神状态检查表(MMSE(®))评估每个受试者的认知状态,得分<24表明存在认知障碍。使用Lawton日常生活工具性活动(IADL)问卷评估功能状态,并通过完成系统可用性量表(SUS)对主观可用性进行整体评估。使用非参数统计和相关分析来确定认知受损和未受损受试者之间是否存在显著差异。
招募了19名受试者并完成了该方案。受试者群体主要为白人、女性、80岁以上且受教育程度高于平均水平。MMSE(®)得分与任务成功率百分比之间存在显著关系(z = -2.03,p = 0.04)。MMSE(®)得分≥24(无认知障碍)的受试者平均成功完成了69.0%的任务,而认知受损组(<24)的表现为34.7%。未受损组中有6名受试者也成功达到了85%(7题答对6题)的阈值。没有认知障碍(MMSE(®)<24)的受试者完成的任务超过5/7(71.4%)。两名受损受试者未能完成所有任务。发现MMSE(®)的三个子部分(日期、地点和倒着拼写“world”)与任务成功率百分比显著相关(p<0.05)。任务成功率与IADL得分(z = -3.826,p<0.0001)和SUS得分(r = 0.467,p = 0.0429)相关。
像EMMA(®)这样的给药装置有可能通过将提醒系统与远程医疗监测和控制功能相结合来改善药物管理。然而,被判定为“认知受损”(MMSE(®)<24)的受试者任务成功率百分比明显低于“未受损”(≥24)的受试者,这表明在使用EMMA(®)之前对患者进行认知筛查可能是明智的。需要进一步研究来测试在没有认知障碍的ALF居民中使用EMMA(®),以确定这项技术是否能提高药物依从性。